Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

40%

2 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Early Phase 1
2(50.0%)
Phase 3
1(25.0%)
Phase 4
1(25.0%)
4Total
Early Phase 1(2)
Phase 3(1)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT06751654Completed

Can Total Mechanical Power Be a Determinant of Weaning Failure in Chronic Obstructive Pulmonary Disease (COPD)?

Role: collaborator

NCT04486508Phase 3Completed

Intermediate-dose vs Standard Prophylactic Anticoagulation and Statin vs Placebo in ICU Patients With COVID-19

Role: collaborator

NCT02371473Phase 4Unknown

Effect of Acetazolamide on Central Sleep Apnea Related to Opium Consumption

Role: collaborator

NCT01683981Early Phase 1Unknown

Exercise Capacity and Quality of Life in Patients With PPH Receiving Short Term Oral L-Citrulline Malate

Role: lead

NCT01917123Early Phase 1Unknown

The Effect of L-Citrulline Malate on Ankle Brachial Index Among Patients With Coronary Heart Disease

Role: lead

All 5 trials loaded